This study will examine the development of stem cells (very immature cells produced by the bone marrow) and their potential to change into cells of other organ types. These cells will be studied for their potential use in creating replacement tissue for diseases ranging from diabetes to Parkinson's.

Healthy volunteers 18 years of age or older may be eligible for this study. Candidates will be screened with a medical history, physical examination, and blood tests.

Participants will undergo a process called 'stem cell mobilization and apheresis' to collect bone marrow stem cells. For five days before the collection they will receive injections of a hormone called G-CSF, which stimulates release of stem cells from the bone marrow into the bloodstream. On the fifth day of the injections, stem cells will be collected through apheresis. For this procedure, blood is collected through a catheter (plastic tube) placed in an arm vein and directed into a cell separator machine. There, the white cells and stem cells are separated from the other blood components through a spinning process and collected in a bag inside the machine. The rest of the blood is returned to the donor through a catheter in the other arm.

Condition	Treatment or Intervention
Healthy	Drug: G-CSF  Procedure: Apheresis

Further Study Details: 

Expected Total Enrollment:  999999

The concept that renewal of various tissues and organs at steady state or following damage relies upon a small population of locally residing tissue specific 'stem cells' has remained unchallenged for decades; however, recent work by several groups has demonstrated a remarkable capacity of cells from one tissue to participate in the repair or repopulation of disparate organs, a process termed 'transdifferentiation'. Stem cells from adult bone marrow represent an ideal stem cell source based on their ease of collection. In order to begin to explore the potential of adult bone marrow, we propose in vitro studies to examine the regulation of both normal differentiation and transdifferentiation of hematopoietic stem cells collected from adult volunteers. In order to obtain adult hematopoietic stem cells in large numbers for in vitro studies, volunteers will undergo mobilization with G-CSF for 5 consecutive days followed by large volume apheresis on the 5th day of G-CSF injection. The harvested product will be immunomagnetically purified for the primitive progenitor population and viably cryopreserved in multiple aliquots.

Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

INCLUSION CRITERIA:
Age 18 or greater.
Normal renal function: creatinine less than1.5 mg/dL, proteinuria less than1+.
Normal liver function: bilirubin less than1.5 mg/dL, transaminases within normal limits.
Normal blood counts: WBC 3,000-10,000/mm3, granulocytes greater than 1,500/mm3, platelets greater than150,000/mm3, hemoglobin greater than12.5g/dL, MCV within normal limits.
Female volunteers of childbearing age should have a negative serum pregnancy test within one week of beginning G-CSF administration.
Meets NIH Department of Transfusion Medicine (DTM) eligibility criteria for blood component donation for in vitro research use (negative serologic tests for syphilis, hepatitis B and C, HIV, and HTLV-1).
Ability to give informed consent to participate in the protocol.
EXCLUSION CRITERIA:
Any underlying hematologic disorder including sickle cell disease.
Active viral, bacterial, fungal, or parasitic infection.
History of autoimmune disease, such as rheumatoid arthritis or systemic lupus erythematosus.
History of cancer excluding squamous carcinoma of the skin and cervical carcinoma in situ.
History of cardiovascular disease or related symptoms such as chest pain or shortness of breath.
Any positive serum screening test as listed below.
Allergy to G-CSF or bacterial E. coli products.
Splenic enlargement at baseline on ultrasound.

Maryland
      National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 9000 Rockville Pike,  Bethesda,  Maryland,  20892,  United States; Recruiting

Study ID Numbers:  020160; 02-DK-0160
Record last reviewed:  January 7, 2005
Last Updated:  January 31, 2005
Record first received:  April 9, 2002
ClinicalTrials.gov Identifier:  NCT00033774
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08